| Name: | Acarbose EP Impurity D |
| Catalogue No. | VL5070005 |
| CAS No. | N/A |
| Molecular Formula | C19H33NO13 |
| Molecular Weight | 483.47 |
| Status | Under Development |
| IUPAC Name | (3R,4R,5S,6R)-5-(((2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-(((1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl)amino)tetrahydro-2H-pyran-2-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-2,3,4-triol |
| Description | Acarbose EP Impurity D is an impurity of Acarbose that delays the production of monosaccharides by inhibiting the a-glucosidases. It is used in the treatment of patients with non-insulin-dependent or insulin-dependent diabetes mellitus. It is also being studied in areas such as dumping syndrome, reactive hypoglycemia, and types IIb and IV hyperlipoproteinaemias. |
| References | Wang, Ya-Jun, et al. “Analysis and Determination of Anti-Diabetes Drug Acarbose and Its Structural Analogs.” Current Pharmaceutical Analysis, vol. 7, no. 1, Feb. 2011, pp. 12–20, https://doi.org/10.2174/157341211794708721. Clissold, Stephen P., and Clive Edwards. “Acarbose.” Drugs, vol. 35, no. 3, Mar. 1988, pp. 214–43, https://doi.org/10.2165/00003495-198835030-00003. |
